Akebia Therapeutics (AKBA)
1.21
-0.05 (3.97%)
Upcoming Events
Latest Headlines
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026 4:05 PM - Globe NewsWire
Form 4 Akebia Therapeutics, For: Jun 29 Filed by: Ostrowski Erik
July 1, 2026 4:34 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)
July 1, 2026 7:03 AM - StreetInsider
Form 8-K Akebia Therapeutics, For: Jun 30
June 30, 2026 8:05 AM - SEC Filing
Vafseo trial stopped early after interim data shows fewer hospitalizations
June 30, 2026 8:02 AM - StreetInsider
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
June 30, 2026 8:01 AM - Globe NewsWire
Form 144 Akebia Therapeutics, Filed by: Ostrowski Erik
June 29, 2026 8:38 PM - SEC Filing
Form 4 Akebia Therapeutics, For: Jun 17 Filed by: Wolf Myles
June 22, 2026 4:25 PM - SEC Filing
Form 4 Akebia Therapeutics, For: Jun 17 Filed by: Smith Cynthia
June 22, 2026 4:24 PM - SEC Filing
Form 4 Akebia Therapeutics, For: Jun 17 Filed by: ROGERS MICHAEL W
June 22, 2026 4:22 PM - SEC Filing
Form 4 Akebia Therapeutics, For: Jun 17 Filed by: FRIESON RON
June 22, 2026 4:20 PM - SEC Filing
Form 8-K Akebia Therapeutics, For: Jun 17
June 22, 2026 4:17 PM - SEC Filing
Form 4 Akebia Therapeutics, For: Jun 17 Filed by: ZUMWALT LEANNE M
June 22, 2026 4:11 PM - SEC Filing
Form 4 Akebia Therapeutics, For: Jun 17 Filed by: ADAMS ADRIAN
June 22, 2026 4:09 PM - SEC Filing
Akebia Therapeutics strengthens Vafseo patent portfolio with new grant
June 10, 2026 8:02 AM - StreetInsider
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
June 10, 2026 8:00 AM - Globe NewsWire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 1, 2026 4:05 PM - Globe NewsWire
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
May 28, 2026 8:00 AM - Globe NewsWire
Form SCHEDULE 13G Akebia Therapeutics, Filed by: STATE STREET CORP
May 12, 2026 9:46 AM - SEC Filing
Form 10-Q Akebia Therapeutics, For: Mar 31
May 7, 2026 7:25 AM - SEC Filing
Akebia Therapeutics (AKBA) Misses Q1 EPS by 2c
May 7, 2026 7:08 AM - StreetInsider
Form 8-K Akebia Therapeutics, For: May 07
May 7, 2026 7:06 AM - SEC Filing
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights
May 7, 2026 7:01 AM - Globe NewsWire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2026 4:05 PM - Globe NewsWire
Akebia reports vadadustat reduces mortality in kidney disease patients
May 4, 2026 8:04 AM - StreetInsider
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal
May 4, 2026 8:00 AM - Globe NewsWire
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights
April 30, 2026 4:06 PM - Globe NewsWire
Form ARS Akebia Therapeutics, For: Dec 31
April 29, 2026 6:05 AM - SEC Filing
Form DEFA14A Akebia Therapeutics,
April 28, 2026 4:14 PM - SEC Filing
Form DEF 14A Akebia Therapeutics, For: Apr 28
April 28, 2026 4:13 PM - SEC Filing
Full Article List
